DKSH has entered into an exclusive partnership with R-Biomeds to bring the necessary medication to patients in Cambodia
US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
The Notes shall not be offered or sold in India
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2
Subscribe To Our Newsletter & Stay Updated
